Production (Stage)
BioVaxys Technology Corp.
BVAXF
$0.0229
$0.00031.33%
OTC PK
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 123.64% | 86.74% | 36.31% | 11.52% | -19.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 125.16% | 87.03% | 28.75% | -1.44% | -33.22% |
| Operating Income | -125.16% | -87.03% | -28.75% | 1.44% | 33.22% |
| Income Before Tax | -16.41% | 12.67% | 49.32% | 74.27% | 56.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.41% | 12.67% | 49.32% | 74.27% | 56.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.41% | 12.67% | 49.32% | 74.27% | 56.22% |
| EBIT | -125.16% | -87.03% | -28.75% | 1.44% | 33.22% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 29.62% | 47.69% | 72.15% | 82.70% | 68.45% |
| Normalized Basic EPS | 50.28% | 57.89% | 67.28% | 67.26% | -18.79% |
| EPS Diluted | 29.62% | 47.69% | 72.15% | 82.70% | 68.45% |
| Normalized Diluted EPS | 50.28% | 57.89% | 67.28% | 67.26% | -18.79% |
| Average Basic Shares Outstanding | 56.94% | 64.34% | 52.10% | 44.57% | 43.98% |
| Average Diluted Shares Outstanding | 56.94% | 64.34% | 52.10% | 44.57% | 43.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |